Seyed-Morteza Javadirad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seyed-Morteza Javadirad has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Mohsen Kolahdouzan
Department of Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
5 shared publicationsMohammad Mokhtari
Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
4 shared publicationsGhazal Esfandiarpour
Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
3 shared publicationsZahra Jafari
Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
3 shared publicationsAhmed Almuslimawi
Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
2 shared publications- Ali Akbar Ehsanpour
Department of Plant and Animal Biology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
2 shared publications
Latest Publications
- 28 May 2026
- Published by Springer Nature in Calcified Tissue International
- Vol. 117  (1)
Maternal Sleep Quality and Early-Life Epigenetic Programming of Bone-Related Genes in Neonatal Cord Blood: Findings from the PERSIAN Birth Cohort, Isfahan
In this cohort, we explored the DNA methylation changes of 3 genes of the canonical Wnt/β-catenin and RANKL/OPG pathways related to bone homeostasis in cord blood at birth. Those mothers with poor sleep quality in the first trimester of pregnancy had 5.9 times higher odds of complete OPG methylation compared to those with good sleep (adjusted OR = 5.9; 95% CI 1.04-33.0; p = 0.045). Maternal lifestyle factors during pregnancy can influence fetal development through epigenetic mechanisms, potentially affecting neonatal skeletal programming and long-term bone health. Sleep quality is an important, modifiable maternal factor, but its role in shaping epigenetic regulation of bone development remains unclear. We aimed to investigate the association between maternal sleep quality during pregnancy and DNA methylation of key genes of the canonical Wnt/β-catenin signaling pathway, Wnt Family Member 10B (WNT10B), β-catenin (CTNNB1), and osteoprotegerin (OPG or TNFRSF11B) in the offspring's cord blood samples at birth. A total of 300 pregnant women were recruited as a sub-study of the PERSIAN Birth Cohort-Isfahan. Maternal sleep patterns were assessed using the Pittsburgh Sleep Quality Index (PSQI). Methylation at cytosine-guanine (CpG) dinucleotide sites within the promoters of WNT10B, β-catenin, and OPG was quantified in offspring's cord blood at birth, and associations with maternal sleep quality across all trimesters were assessed. Poor sleep quality in the first trimester was significantly associated with increased OPG methylation (adjusted OR = 1.40, 95% CI 1.05-1.8, p = 0.023). Mothers with poor sleep quality (PSQI ≥ 5) in the first trimester had 5.9 times higher odds of complete OPG methylation compared to those with good sleep quality (adjusted OR = 5.9, 95% CI 1.04-33.0, p = 0.045). However, associations with WNT10B and β-catenin were not statistically significant. Maternal sleep quality during early gestation may influence the DNA methylation and epigenetic programming of bone-related genes in neonatal cord blood, emphasizing the importance of maternal lifestyle as a modifiable factor shaping early-life bone health.
- 28 May 2026
- Published by Springer Nature in Calcified Tissue International
- Vol. 117  (1)
Maternal Sleep Quality and Early-Life Epigenetic Programming of Bone-Related Genes in Neonatal Cord Blood: Findings from the PERSIAN Birth Cohort, Isfahan
In this cohort, we explored the DNA methylation changes of 3 genes of the canonical Wnt/β-catenin and RANKL/OPG pathways related to bone homeostasis in cord blood at birth. Those mothers with poor sleep quality in the first trimester of pregnancy had 5.9 times higher odds of complete OPG methylation compared to those with good sleep (adjusted OR = 5.9; 95% CI 1.04-33.0; p = 0.045). Maternal lifestyle factors during pregnancy can influence fetal development through epigenetic mechanisms, potentially affecting neonatal skeletal programming and long-term bone health. Sleep quality is an important, modifiable maternal factor, but its role in shaping epigenetic regulation of bone development remains unclear. We aimed to investigate the association between maternal sleep quality during pregnancy and DNA methylation of key genes of the canonical Wnt/β-catenin signaling pathway, Wnt Family Member 10B (WNT10B), β-catenin (CTNNB1), and osteoprotegerin (OPG or TNFRSF11B) in the offspring's cord blood samples at birth. A total of 300 pregnant women were recruited as a sub-study of the PERSIAN Birth Cohort-Isfahan. Maternal sleep patterns were assessed using the Pittsburgh Sleep Quality Index (PSQI). Methylation at cytosine-guanine (CpG) dinucleotide sites within the promoters of WNT10B, β-catenin, and OPG was quantified in offspring's cord blood at birth, and associations with maternal sleep quality across all trimesters were assessed. Poor sleep quality in the first trimester was significantly associated with increased OPG methylation (adjusted OR = 1.40, 95% CI 1.05-1.8, p = 0.023). Mothers with poor sleep quality (PSQI ≥ 5) in the first trimester had 5.9 times higher odds of complete OPG methylation compared to those with good sleep quality (adjusted OR = 5.9, 95% CI 1.04-33.0, p = 0.045). However, associations with WNT10B and β-catenin were not statistically significant. Maternal sleep quality during early gestation may influence the DNA methylation and epigenetic programming of bone-related genes in neonatal cord blood, emphasizing the importance of maternal lifestyle as a modifiable factor shaping early-life bone health.
- Open Access
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 41276
A Comprehensive multi-network analysis of ceRNAs and transcription factors for papillary thyroid carcinoma diagnosis and prognosis
Papillary thyroid carcinoma (PTC) is a malignancy with an ambiguous etiology. The competitive endogenous RNA (ceRNA) hypothesis provides a framework for clarifying the molecular mechanisms that drive carcinogenesis. In this study, we constructed a novel ceRNA network to identify reliable diagnostic and prognostic indicators applicable across all stages of PTC. Transcriptome analysis was performed to identify stage-specific hub genes using the MCC, IVI, and MCODE algorithms. A novel five-layer ceRNA network and its associated regulatory network (DE-TF) were constructed. Receiver operating characteristic curves were used to evaluate the diagnostic performance of elements within both networks. A risk assessment model was developed by identifying key genes from the ceRNA and DE-TF components through univariable Cox regression and LASSO regression analyses. RNA-seq findings were validated by RT-qPCR. The correlations between gene expression levels and blood calcium levels were examined. The ceRNA and DE-TF networks contained 33 and 21 components, respectively. Logistic regression analysis identified PKMYT1, E2F1, NFATC1, STAT6, E2F3, LINC02910, GAS5, and TK1 as reliable diagnostic markers for PTC, achieving an AUC of 96.9%. Among these, PKMYT1 and GAS5 were stage-specific markers, showing significant upregulation in highly aggressive PTC tumors compared to less aggressive ones. Both genes demonstrated strong diagnostic value in differentiating high- from low-aggressive tumors, with AUCs of 0.81 and 0.87, respectively. circMET, which was overexpressed in both low- and high-aggressive tumors, showed diagnostic potential in distinguishing low-aggressive tumors from normal adjacent tissues (AUC = 0.81). GAS5 expression demonstrated an association with blood calcium levels. The SERN prognostic model, including STAT6, E2F1, RMI2, and NR4A1, illustrates the importance of these four genes as reliable prognostic markers for overall survival in PTC. Three components of the ceRNA network-PKMYT1, GAS5, and circMET-were significantly associated with PTC aggressiveness. PKMYT1 and GAS5 demonstrated strong diagnostic value in distinguishing high-aggressive from low-aggressive tumors, while circMET showed notable diagnostic efficacy in differentiating low-aggressive PTC tumors from adjacent normal tissues. Furthermore, GAS5 expression levels were correlated with blood calcium levels.
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 41276
Open AccessA Comprehensive multi-network analysis of ceRNAs and transcription factors for papillary thyroid carcinoma diagnosis and prognosis
Papillary thyroid carcinoma (PTC) is a malignancy with an ambiguous etiology. The competitive endogenous RNA (ceRNA) hypothesis provides a framework for clarifying the molecular mechanisms that drive carcinogenesis. In this study, we constructed a novel ceRNA network to identify reliable diagnostic and prognostic indicators applicable across all stages of PTC. Transcriptome analysis was performed to identify stage-specific hub genes using the MCC, IVI, and MCODE algorithms. A novel five-layer ceRNA network and its associated regulatory network (DE-TF) were constructed. Receiver operating characteristic curves were used to evaluate the diagnostic performance of elements within both networks. A risk assessment model was developed by identifying key genes from the ceRNA and DE-TF components through univariable Cox regression and LASSO regression analyses. RNA-seq findings were validated by RT-qPCR. The correlations between gene expression levels and blood calcium levels were examined. The ceRNA and DE-TF networks contained 33 and 21 components, respectively. Logistic regression analysis identified PKMYT1, E2F1, NFATC1, STAT6, E2F3, LINC02910, GAS5, and TK1 as reliable diagnostic markers for PTC, achieving an AUC of 96.9%. Among these, PKMYT1 and GAS5 were stage-specific markers, showing significant upregulation in highly aggressive PTC tumors compared to less aggressive ones. Both genes demonstrated strong diagnostic value in differentiating high- from low-aggressive tumors, with AUCs of 0.81 and 0.87, respectively. circMET, which was overexpressed in both low- and high-aggressive tumors, showed diagnostic potential in distinguishing low-aggressive tumors from normal adjacent tissues (AUC = 0.81). GAS5 expression demonstrated an association with blood calcium levels. The SERN prognostic model, including STAT6, E2F1, RMI2, and NR4A1, illustrates the importance of these four genes as reliable prognostic markers for overall survival in PTC. Three components of the ceRNA network-PKMYT1, GAS5, and circMET-were significantly associated with PTC aggressiveness. PKMYT1 and GAS5 demonstrated strong diagnostic value in distinguishing high-aggressive from low-aggressive tumors, while circMET showed notable diagnostic efficacy in differentiating low-aggressive PTC tumors from adjacent normal tissues. Furthermore, GAS5 expression levels were correlated with blood calcium levels.
- Open Access
- 11 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 1-3
Publisher Correction: Adrenocortical carcinoma survival gene HMMR was identified as being targeted by fluorouracil and epirubicin using a gene coexpression network-based drug repositioning strategy
- 11 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 1-3
Open AccessPublisher Correction: Adrenocortical carcinoma survival gene HMMR was identified as being targeted by fluorouracil and epirubicin using a gene coexpression network-based drug repositioning strategy
- 18 September 2025
- Published by Springer Nature in Network Modeling Analysis in Health Informatics and Bioinformatics
- Vol. 14  (1) , 1-16
Identifying potential biomarkers of non-obstructive azoospermia using a comprehensive bioinformatics approach
- 18 September 2025
- Published by Springer Nature in Network Modeling Analysis in Health Informatics and Bioinformatics
- Vol. 14  (1) , 1-16
Identifying potential biomarkers of non-obstructive azoospermia using a comprehensive bioinformatics approach
- Open Access
- 17 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 25912
Adrenocortical carcinoma survival gene HMMR was identified as being targeted by fluorouracil and epirubicin using a gene coexpression network-based drug repositioning strategy
Adrenocortical carcinoma (ACC), with poor prognosis, is one of the most aggressive endocrine cancers. Surgery is the mainstay of treatment; nevertheless, chemotherapy is usually needed. Mitotane, the medication licenced for ACC, has had mixed results. Drug repositioning based on gene coexpression networks has proven to be an effective method of discovering potential cancer treatments. A total of 139 human specimens were examined, comprising 106 metastatic ACCs, 14 benign adrenocortical adenomas (ACAs), and 19 normal adrenal cortex tissues. Hub genes were identified using weighted correlation network analysis (WGCNA), and their differential expression was confirmed by microarrays and RNA sequencing. Hub genes were analyzed in more depth for enrichment, coexpression, and protein-protein interaction. Two phases of survival analysis were conducted considering sex. Hub gene expression was associated with TP53 mutations and cancer stage. Hub genes were evaluated using regression analysis. Hub genes were associated with immune cell infiltration. Network analysis identified transcription factors that regulate hub genes. Drug-gene interaction network analyses were performed to reposition existing drugs. WGCNA-PPI analysis revealed 31 hub genes, 11 of which were overexpressed by more than fourfold, as well as HMMR and UBE2T, which were novel genes. All hubs showed significant correlations with survival, tumor staging, and TP53 mutation status in ACC tissues. Women overexpressing CDK1, UBE2C, PCLAF, and CCNB1 were more likely to suffer catastrophic deaths than men. In terms of ACC diagnostic capacity, all hub genes had AUCs greater than 0.90, with TOP2A, CDK1, and CCNB1 having the highest values. All hub genes, except for THYMS and RACGAP1, were negatively correlated with M2 macrophages and CD8 + T cells infiltration. Hub genes were co-expressed and regulated by 21 DE-TFs expressed differently between ACC and normal tissues. Novel pharmaceuticals are represented by fifteen out of thirty-four medications directed at hub genes and DE-TFs. Paclitaxel and cisplatin were the central nodes within the drug-gene network. Multiple drugs target TYMS and TOP2A, making them both promising targets for ACC. Fluorouracil and epirubicin target HMMR novel hub gene. HMMR as a novel ACC hub gene targets by fluorouracil and epirubicin, but fluorouracil has advantageous. The reason for this is that M2 macrophages promote fluorouracil resistance, whereas tumors overexpressing the HMMR gene demonstrate a negative infiltration of macrophages. Hub genes, associated with ACC development and progression, have negative impacts on survival rates, particularly in women. Network analysis shows fluorouracil and epirubicin target the ACC novel hub gene, HMMR. Fluorouracil was more effective due to its impact on M2 macrophage infiltration.
- 17 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15  (1) , 25912
Open AccessAdrenocortical carcinoma survival gene HMMR was identified as being targeted by fluorouracil and epirubicin using a gene coexpression network-based drug repositioning strategy
Adrenocortical carcinoma (ACC), with poor prognosis, is one of the most aggressive endocrine cancers. Surgery is the mainstay of treatment; nevertheless, chemotherapy is usually needed. Mitotane, the medication licenced for ACC, has had mixed results. Drug repositioning based on gene coexpression networks has proven to be an effective method of discovering potential cancer treatments. A total of 139 human specimens were examined, comprising 106 metastatic ACCs, 14 benign adrenocortical adenomas (ACAs), and 19 normal adrenal cortex tissues. Hub genes were identified using weighted correlation network analysis (WGCNA), and their differential expression was confirmed by microarrays and RNA sequencing. Hub genes were analyzed in more depth for enrichment, coexpression, and protein-protein interaction. Two phases of survival analysis were conducted considering sex. Hub gene expression was associated with TP53 mutations and cancer stage. Hub genes were evaluated using regression analysis. Hub genes were associated with immune cell infiltration. Network analysis identified transcription factors that regulate hub genes. Drug-gene interaction network analyses were performed to reposition existing drugs. WGCNA-PPI analysis revealed 31 hub genes, 11 of which were overexpressed by more than fourfold, as well as HMMR and UBE2T, which were novel genes. All hubs showed significant correlations with survival, tumor staging, and TP53 mutation status in ACC tissues. Women overexpressing CDK1, UBE2C, PCLAF, and CCNB1 were more likely to suffer catastrophic deaths than men. In terms of ACC diagnostic capacity, all hub genes had AUCs greater than 0.90, with TOP2A, CDK1, and CCNB1 having the highest values. All hub genes, except for THYMS and RACGAP1, were negatively correlated with M2 macrophages and CD8 + T cells infiltration. Hub genes were co-expressed and regulated by 21 DE-TFs expressed differently between ACC and normal tissues. Novel pharmaceuticals are represented by fifteen out of thirty-four medications directed at hub genes and DE-TFs. Paclitaxel and cisplatin were the central nodes within the drug-gene network. Multiple drugs target TYMS and TOP2A, making them both promising targets for ACC. Fluorouracil and epirubicin target HMMR novel hub gene. HMMR as a novel ACC hub gene targets by fluorouracil and epirubicin, but fluorouracil has advantageous. The reason for this is that M2 macrophages promote fluorouracil resistance, whereas tumors overexpressing the HMMR gene demonstrate a negative infiltration of macrophages. Hub genes, associated with ACC development and progression, have negative impacts on survival rates, particularly in women. Network analysis shows fluorouracil and epirubicin target the ACC novel hub gene, HMMR. Fluorouracil was more effective due to its impact on M2 macrophage infiltration.
- Open Access
- 29 June 2024
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15  (1) , 30095
A procedure for DNA methylation assessment in osteoporosis-related gene promoters of umbilical cord blood: A study on the Prospective Epidemiological Research Studies in Iran (PERSIAN) birth cohort
Introduction: It is believed that DNA methylation can modify disease susceptibility in response to environmental factors as early as the perinatal period. In this study, we aimed to present a streamlined DNA methylation analysis procedure for osteoporosis-related gene promoters in the umbilical cord blood. Methods: The Prospective Epidemiological Research Studies in Iran (PERSIAN) birth cohort was established in 2016. In this study, a total of 300 umbilical cord blood samples were collected at the time of delivery. For all samples, DNA was extracted and converted using sodium bisulfite. Multiple primer sets were designed for Wnt1, Wnt10b, β-catenin, OPG, and RANKL gene promoters in the online MethPrimer platform. Next, bisulfite sequencing PCR (BSP), as the gold standard method for exploring methylated and unmethylated cytosines, was performed in a gradient-controlled setting. The PCR products were then purified and directly sequenced. Subsequently, the chromatograms were interpreted. Results: For Wnt10b, β-catenin, and OPG genes, the converted DNA could be successfully amplified. The frequency of acceptable chromatograms for analysis was 195 for Wnt10b (195/300, 0.65%), 198 for β-catenin (198/300, 0.66%), and 50 for OPG (50/50, 100%). Conclusion: BSP can be efficiently used to investigate the methylation of target gene promoters in umbilical cord blood DNA.
- 29 June 2024
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15  (1) , 30095
Open AccessA procedure for DNA methylation assessment in osteoporosis-related gene promoters of umbilical cord blood: A study on the Prospective Epidemiological Research Studies in Iran (PERSIAN) birth cohort
Introduction: It is believed that DNA methylation can modify disease susceptibility in response to environmental factors as early as the perinatal period. In this study, we aimed to present a streamlined DNA methylation analysis procedure for osteoporosis-related gene promoters in the umbilical cord blood. Methods: The Prospective Epidemiological Research Studies in Iran (PERSIAN) birth cohort was established in 2016. In this study, a total of 300 umbilical cord blood samples were collected at the time of delivery. For all samples, DNA was extracted and converted using sodium bisulfite. Multiple primer sets were designed for Wnt1, Wnt10b, β-catenin, OPG, and RANKL gene promoters in the online MethPrimer platform. Next, bisulfite sequencing PCR (BSP), as the gold standard method for exploring methylated and unmethylated cytosines, was performed in a gradient-controlled setting. The PCR products were then purified and directly sequenced. Subsequently, the chromatograms were interpreted. Results: For Wnt10b, β-catenin, and OPG genes, the converted DNA could be successfully amplified. The frequency of acceptable chromatograms for analysis was 195 for Wnt10b (195/300, 0.65%), 198 for β-catenin (198/300, 0.66%), and 50 for OPG (50/50, 100%). Conclusion: BSP can be efficiently used to investigate the methylation of target gene promoters in umbilical cord blood DNA.
- Open Access
- 28 February 2024
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 90  (4) , 101409
NKX2-1 gene is targeted by H19 lncRNA and is found to be overexpressed in benign nodular goiter tissues
- 28 February 2024
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 90  (4) , 101409
Open AccessNKX2-1 gene is targeted by H19 lncRNA and is found to be overexpressed in benign nodular goiter tissues
- 31 January 2024
- Published by Springer Nature in Biochemical Genetics
- Vol. 62  (6) , 4317-4334
FOXE1 Gene is a Probable Tumor Suppressor Gene with Decreased Expression as Papillary Thyroid Cancers Grow, and is Absent in Anaplastic Thyroid Cancers
Papillary thyroid carcinoma (PTC), the most prevalent cancer of the thyroid, is more common in women than in men. To uncover the expression profile of FOXE1 gene in PTC tumor etiology. Microarray and RNA sequencing data on PTC in humans were analyzed. Eleven PTC tumor tissue samples and their neighboring normal tissue samples were collected. RT-qPCR was performed. Data normality, ROC construction, and logistic regression analysis were conducted. PTC tumors, normal tissues surrounding tumors, patients of different sexes and ages, metastasizing tumors, and tumor variants were assessed for FOXE1 expression. Eleven PTC tissues were obtained from seven women and four men. Among the PTC subtypes, there were two FV-PTCs, four C-PTCs, one microcarcinoma, and four tissues with an unknown subtype. FOXE1 gene expression was significantly increased in PTC tumors with dimensions less than 10 mm (relative expression = 14.437, p = 0.050). A significant increase in FOXE1 gene expression was observed in the normal tissue adjacent to the tumor, which was less than 10 mm in size, compared to the normal tissue adjacent to the tumor, which was larger than 10 mm (relative expression = 41.760, p = 0.0001). Females diagnosed with PTC showed a significant reduction in FOXE1 mRNA levels compared to their male counterparts (relative expression = 0.081, p = 0.042). In contrast to adjacent normal tissue, there was a significant reduction in FOXE1 gene expression in FV-PTC (relative expression = 0.044 and p = 0.0001). PTC tumors under 10mm had higher FOXE1 gene expression than larger tumors; normal tissue adjacent to smaller tumors also had higher FOXE1 expression. Females with PTC, regardless of their subtype, expressed less FOXE1 mRNA than males. FV-PTC tissues exhibited lower expression of FOXE1 mRNA than their adjacent normal tissues.
- 31 January 2024
- Published by Springer Nature in Biochemical Genetics
- Vol. 62  (6) , 4317-4334
FOXE1 Gene is a Probable Tumor Suppressor Gene with Decreased Expression as Papillary Thyroid Cancers Grow, and is Absent in Anaplastic Thyroid Cancers
Papillary thyroid carcinoma (PTC), the most prevalent cancer of the thyroid, is more common in women than in men. To uncover the expression profile of FOXE1 gene in PTC tumor etiology. Microarray and RNA sequencing data on PTC in humans were analyzed. Eleven PTC tumor tissue samples and their neighboring normal tissue samples were collected. RT-qPCR was performed. Data normality, ROC construction, and logistic regression analysis were conducted. PTC tumors, normal tissues surrounding tumors, patients of different sexes and ages, metastasizing tumors, and tumor variants were assessed for FOXE1 expression. Eleven PTC tissues were obtained from seven women and four men. Among the PTC subtypes, there were two FV-PTCs, four C-PTCs, one microcarcinoma, and four tissues with an unknown subtype. FOXE1 gene expression was significantly increased in PTC tumors with dimensions less than 10 mm (relative expression = 14.437, p = 0.050). A significant increase in FOXE1 gene expression was observed in the normal tissue adjacent to the tumor, which was less than 10 mm in size, compared to the normal tissue adjacent to the tumor, which was larger than 10 mm (relative expression = 41.760, p = 0.0001). Females diagnosed with PTC showed a significant reduction in FOXE1 mRNA levels compared to their male counterparts (relative expression = 0.081, p = 0.042). In contrast to adjacent normal tissue, there was a significant reduction in FOXE1 gene expression in FV-PTC (relative expression = 0.044 and p = 0.0001). PTC tumors under 10mm had higher FOXE1 gene expression than larger tumors; normal tissue adjacent to smaller tumors also had higher FOXE1 expression. Females with PTC, regardless of their subtype, expressed less FOXE1 mRNA than males. FV-PTC tissues exhibited lower expression of FOXE1 mRNA than their adjacent normal tissues.
- Open Access
- 11 October 2023
- Published by Brieflands in Jentashapir Journal of Cellular and Molecular Biology
- Vol. 14  (3)
The Act of Diminishing the RTRAF Expression in Benign Thyroid Tissues Represents a Potential Method for Impeding the Progression of Malignancy in Cells
Background: Thyroid cancer is the most common endocrine cancer, and women are almost three times more likely to develop it than men. Objectives: The etiology of thyroid cancer at the genetic level remains elusive. However, a potential involvement of the RNA Transcription, Translation, and Transport Factor (RTRAF) gene in the pathogenesis of this malignancy has been postulated. This gene has been shown to govern the expression of proteins that exert regulatory effects on the transition from the G1 to S phase of the cell cycle. Methods: For this study, 22 papillary thyroid carcinoma (PTC) tissues and 22 healthy tissues were collected. Additionally, 10 benign goiter tissues and 10 healthy tissues were gathered. RNA molecules were fixed, and complementary DNA (cDNA) was produced. Specific primers were used to measure the RTRAF gene expression. Statistical analysis was conducted using REST 2009 software. Results: Upon assessing the quality and quantity of RNA, it was ascertained that the extracted RNA molecules exhibited minimal damage and were found to be appropriately concentrated for cDNA production. The amplification of the RTRAF gene was carried out accurately, as evidenced by the melting curve. A noteworthy decline in the RTRAF gene expression was detected in the benign goiter tissue compared to the adjacent healthy tissue, with a relative expression of 0.154 and a statistical value of P = 0.002. Conversely, there was no significant difference in the RTRAF gene expression between PTC and the adjacent healthy tissue, with a P-value of 0.808. Conclusions: The reduced RTRAF gene expression in benign thyroid tumors may hinder cancer cell growth, as no difference was observed between malignant PTC tumor tissues and their healthy tissues.
- 11 October 2023
- Published by Brieflands in Jentashapir Journal of Cellular and Molecular Biology
- Vol. 14  (3)
Open AccessThe Act of Diminishing the RTRAF Expression in Benign Thyroid Tissues Represents a Potential Method for Impeding the Progression of Malignancy in Cells
Background: Thyroid cancer is the most common endocrine cancer, and women are almost three times more likely to develop it than men. Objectives: The etiology of thyroid cancer at the genetic level remains elusive. However, a potential involvement of the RNA Transcription, Translation, and Transport Factor (RTRAF) gene in the pathogenesis of this malignancy has been postulated. This gene has been shown to govern the expression of proteins that exert regulatory effects on the transition from the G1 to S phase of the cell cycle. Methods: For this study, 22 papillary thyroid carcinoma (PTC) tissues and 22 healthy tissues were collected. Additionally, 10 benign goiter tissues and 10 healthy tissues were gathered. RNA molecules were fixed, and complementary DNA (cDNA) was produced. Specific primers were used to measure the RTRAF gene expression. Statistical analysis was conducted using REST 2009 software. Results: Upon assessing the quality and quantity of RNA, it was ascertained that the extracted RNA molecules exhibited minimal damage and were found to be appropriately concentrated for cDNA production. The amplification of the RTRAF gene was carried out accurately, as evidenced by the melting curve. A noteworthy decline in the RTRAF gene expression was detected in the benign goiter tissue compared to the adjacent healthy tissue, with a relative expression of 0.154 and a statistical value of P = 0.002. Conversely, there was no significant difference in the RTRAF gene expression between PTC and the adjacent healthy tissue, with a P-value of 0.808. Conclusions: The reduced RTRAF gene expression in benign thyroid tumors may hinder cancer cell growth, as no difference was observed between malignant PTC tumor tissues and their healthy tissues.
- Open Access
- 18 September 2023
- Published by Springer Nature in Research Square
Five new hub genes that have an impact on the survival rate of adrenocortical carcinoma were discovered using a correlation network approach in a comprehensive meta-analysis
Identifying hub genes that contribute to the aggressiveness of adrenocortical carcinoma (ACC) is of the utmost importance. The GEO database found 14 microarray datasets for Homo sapiens, but some were excluded due to missing phenotype information, lncRNA expression, and treatment exposure. The study involved 171 human specimens, including 128 ACCs, 17 ACAs, and 26 normal adrenal cortex samples. Weighted correlation network analysis (WGCNA) was utilized to identify ACC hub genes and their differential expression was assessed with microarray meta-analysis. Survival analysis was conducted in two steps, with and without sex. The expression level of survival genes was compared between ACC stages, and the impact of TP53 gene mutations was assessed. Enrichment, coexpression, and network analyses were performed. The diagnostic and predictive potential of the genes was evaluated using single gene and multivariate regression analyses. It was discovered that twenty hub genes exhibited increased expression in both benign and malignant tissues. Moreover, a set of five genes demonstrated a significant correlation with ACC survival, namely DNAJC9, ATAD2, RFC4, GGH, and PCLAF. The genes GGH and RFC4 were recently discovered associated with ACC. Women with survival genes overexpression experienced earlier catastrophic deaths than men. Patients with TP53 mutations showed PCLAFand DNAJC9 overexpression. There was an association between increased RFC4gene expression and ACC tumor progression. Coexpression analysis substantiated the fact that survival genes exhibited a significant positive correlation. An analysis of the network revealed that RFC4 and ATAD2 were the most essential proteins. GGH had the greatest diagnostic potential for ACC and combining GGH, PCLAF, DNAJC9 and RFC4 led to an outstanding ACC diagnosis. A limitation of the study was the rarity of ACC tumors.
- 18 September 2023
- Published by Springer Nature in Research Square
Open AccessFive new hub genes that have an impact on the survival rate of adrenocortical carcinoma were discovered using a correlation network approach in a comprehensive meta-analysis
Identifying hub genes that contribute to the aggressiveness of adrenocortical carcinoma (ACC) is of the utmost importance. The GEO database found 14 microarray datasets for Homo sapiens, but some were excluded due to missing phenotype information, lncRNA expression, and treatment exposure. The study involved 171 human specimens, including 128 ACCs, 17 ACAs, and 26 normal adrenal cortex samples. Weighted correlation network analysis (WGCNA) was utilized to identify ACC hub genes and their differential expression was assessed with microarray meta-analysis. Survival analysis was conducted in two steps, with and without sex. The expression level of survival genes was compared between ACC stages, and the impact of TP53 gene mutations was assessed. Enrichment, coexpression, and network analyses were performed. The diagnostic and predictive potential of the genes was evaluated using single gene and multivariate regression analyses. It was discovered that twenty hub genes exhibited increased expression in both benign and malignant tissues. Moreover, a set of five genes demonstrated a significant correlation with ACC survival, namely DNAJC9, ATAD2, RFC4, GGH, and PCLAF. The genes GGH and RFC4 were recently discovered associated with ACC. Women with survival genes overexpression experienced earlier catastrophic deaths than men. Patients with TP53 mutations showed PCLAFand DNAJC9 overexpression. There was an association between increased RFC4gene expression and ACC tumor progression. Coexpression analysis substantiated the fact that survival genes exhibited a significant positive correlation. An analysis of the network revealed that RFC4 and ATAD2 were the most essential proteins. GGH had the greatest diagnostic potential for ACC and combining GGH, PCLAF, DNAJC9 and RFC4 led to an outstanding ACC diagnosis. A limitation of the study was the rarity of ACC tumors.